Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.

Zhang T, Rong N, Chen J, Zou C, Jing H, Zhu X, Zhang W.

PLoS One. 2013 Nov 5;8(11):e79162. doi: 10.1371/journal.pone.0079162. eCollection 2013.

2.

FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.

Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC.

Lung Cancer. 2013 Feb;79(2):173-9. doi: 10.1016/j.lungcan.2012.10.019. Epub 2012 Nov 20.

PMID:
23177020
3.

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J.

Oncol Rep. 2012 Apr;27(4):979-86. doi: 10.3892/or.2011.1591. Epub 2011 Dec 13.

4.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

PMID:
23287853
5.

IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.

Tian Z, Yao G, Song H, Zhou Y, Geng J.

Cell Physiol Biochem. 2014;34(5):1578-88. doi: 10.1159/000366361. Epub 2014 Oct 31.

PMID:
25402559
6.

Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.

Xu C, Hao K, Hu H, Sheng Z, Yan J, Wang Q, Yu L.

Lung Cancer. 2014 Nov;86(2):268-73. doi: 10.1016/j.lungcan.2014.09.010. Epub 2014 Sep 22.

PMID:
25262426
7.

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.

Yan D, Wei P, An G, Chen W.

J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149.

8.

Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

Du G, Yang Y, Zhang Y, Sun T, Liu W, Wang Y, Li J, Zhang H.

Cancer Chemother Pharmacol. 2013 Apr;71(4):893-904. doi: 10.1007/s00280-013-2080-6. Epub 2013 Jan 26. Erratum in: Cancer Chemother Pharmacol. 2013 Jul;72(1):275. Yang, Yingming [corrected to Yang, Yiming].

PMID:
23355038
9.

[Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].

Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.

Ai Zheng. 2004 Jul;23(7):845-50. Chinese.

PMID:
15248926
10.

Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.

Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D.

Lung Cancer. 2013 Nov;82(2):324-9. doi: 10.1016/j.lungcan.2013.08.001. Epub 2013 Aug 11.

PMID:
23993732
11.

Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.

Li J, Li ZN, Du YJ, Li XQ, Bao QL, Chen P.

Clin Lung Cancer. 2009 Nov;10(6):414-21. doi: 10.3816/CLC.2009.n.078.

PMID:
19900859
12.

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis.

Xu J, Yue CF, Zhou WH, Qian YM, Zhang Y, Wang SW, Liu AW, Liu Q.

J Transl Med. 2014 Jul 31;12:200. doi: 10.1186/1479-5876-12-200.

13.

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.

Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R, Montuenga LM.

PLoS One. 2015 Apr 27;10(4):e0124670. doi: 10.1371/journal.pone.0124670. eCollection 2015.

14.

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.

He L, Teng Y, Jin B, Zhao M, Yu P, Hu X, Zhang J, Li S, Gao Y, Liu Y.

BMC Cancer. 2010 Dec 14;10:681. doi: 10.1186/1471-2407-10-681.

15.

Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution.

Inal A, Kaplan MA, Kucukoner M, Urakci Z, Karakus A, Isikdogan A.

Asian Pac J Cancer Prev. 2012;13(4):1281-4.

16.

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH.

Lung Cancer. 2011 Nov;74(2):310-7. doi: 10.1016/j.lungcan.2011.03.016. Epub 2011 Apr 29.

PMID:
21529986
17.

Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.

Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ, Lee DG, Kim MH, Lee JH, Chung MJ.

Pathol Res Pract. 2013 Jun;209(6):365-70. doi: 10.1016/j.prp.2013.03.011. Epub 2013 Apr 15.

PMID:
23702379
18.

SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.

Shin DH, Choi YJ, Park JW.

Cancer Res. 2014 Jan 1;74(1):298-308. doi: 10.1158/0008-5472.CAN-13-2620. Epub 2013 Nov 15.

19.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.

Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26.

PMID:
20504223
20.

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM.

Lancet Oncol. 2011 Nov;12(12):1125-33. doi: 10.1016/S1470-2045(11)70259-5. Epub 2011 Oct 21.

PMID:
22019520
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk